Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.22.2.2
Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Net sales $ 269,655 $ 257,719  
Operating income 56,317 63,222  
Costs recognized on sale of acquired inventory (300) (1,512)  
Corporate general, selling, and administrative expenses (99,375) (86,175)  
Total intangible assets, net 585,534   $ 531,522
Consumables [Member]      
Net sales 216,430 205,691  
Protein Sciences [Member]      
Restructuring costs (2,170)    
Diagnostics and Genomics [Member]      
Restructuring costs     $ (242)
Operating Segments [Member]      
Operating income 94,580 97,563  
Costs recognized on sale of acquired inventory (300) (1,512)  
Amortization of acquisition related intangible assets (19,283) (18,389)  
Impact of partially-owned consolidated subsidiaries(1) 647 (1,562)  
Acquisition related expenses (297) 2,377  
Stock based compensation, inclusive of employer taxes (15,458) (13,860)  
Restructuring costs (2,170) (1,185)  
Operating Segments [Member] | Protein Sciences [Member]      
Net sales 199,949 197,186  
Operating income 85,942 90,100  
Operating Segments [Member] | Diagnostics and Genomics [Member]      
Net sales 69,904 60,985  
Operating income 8,638 7,463  
Intersegment Eliminations [Member]      
Net sales (198) (452)  
Corporate, Non-Segment [Member]      
Corporate general, selling, and administrative expenses $ (1,402) $ (210)